Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Moleculin Biotech Inc MBRX

Healthcare Biotechnology
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug... see more

Recent & Breaking News (NDAQ:MBRX)

Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients

PR Newswire November 19, 2019

Moleculin Announces Beginning of Preclinical Development of New Approach to Pancreatic Cancer

PR Newswire November 13, 2019

Moleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial

PR Newswire November 12, 2019

Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2019

PR Newswire November 12, 2019

Moleculin Announces New Data Confirms Anti-tumor Efficacy of Annamycin in Both Human and Murine AML Models

PR Newswire October 29, 2019

Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications

PR Newswire October 22, 2019

Moleculin Announces its Sponsored Research at MD Anderson Cancer Center Has Resulted in the Filing of Patent Protection for New Discovery

PR Newswire September 16, 2019

Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2019

PR Newswire August 16, 2019

Moleculin Announces Completion of Lymphoma Trial Enrollment

PR Newswire August 13, 2019

Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models

PR Newswire August 6, 2019

Moleculin Announces Annamycin in Acute Myeloid Leukemia in Poland Advances to 3rd Cohort

PR Newswire July 18, 2019

Moleculin Files for New Patents for Annamycin After Receiving FDA Approval of Fast Track Designation

PR Newswire July 10, 2019

Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2019

PR Newswire May 14, 2019

Moleculin Announces Additional Positive Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia in Europe

PR Newswire May 7, 2019

Generex Biotechnology Announces Organizational Roadmap & Investor Conference Call: Update on Product Launch, New Acquisitions, Financing, Expansion Initiatives & Strategic Plans

PR Newswire April 29, 2019

Positive Results From HMN Lithium Project P.E.A.

PR Newswire April 29, 2019

US Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First Patient Showing Positive Initial Treatment

PR Newswire April 29, 2019

Moleculin Announces $15.0 Million Registered Direct Offering

PR Newswire April 23, 2019

Moleculin Announces Conference Call to Discuss Significant Discovery For Lung Cancer and FDA Activity on Wednesday, April 24, 2019

PR Newswire April 22, 2019

Moleculin Receives FDA Approval of Fast Track Designation for Annamycin

PR Newswire April 18, 2019